Source: Eur Respir J, 58 (4) 2002819; 10.1183/13993003.02819-2020
Disease area: Paediatric lung diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Kay Wang, Malcolm G. Semple, Michael Moore, Alastair D. Hay, Sharon Tonner, Ushma Galal, Jenna Grabey, Tricia Carver, Rafael Perera, Ly-Mee Yu, Jill Mollison, Paul Little, Andrew Farmer, Christopher C. Butler, Anthony Harnden. The early use of Antibiotics for at Risk CHildren with InfluEnza-like illness (ARCHIE): a double-blind randomised placebo-controlled trial. Eur Respir J, 58 (4) 2002819; 10.1183/13993003.02819-2020

Member's Comments

No comment yet.

Related content which might interest you: Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021 Year: 2021 Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial Source: Eur Respir J, 59 (1) 2100752; 10.1183/13993003.00752-2021 Year: 2022 Randomised, double-blind, placebo-controlled trial of EPS® 7630 in adults with COPD Source: Annual Congress 2009 - Healthcare and treatment of COPD Year: 2009 Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO) Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021 Year: 2022 Antibiotic in non-purulent hospitalised-treated exacerbations of COPD: a randomised double-blind placebo-controlled trial Source: International Congress 2019 – Airway infection in COPD Year: 2019 Effectiveness of influenza vaccination in asthmatic children: randomised, double-blind, placebo-controlled trial Source: Eur Respir J 2002; 20: Suppl. 38, 146s Year: 2002 RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 Azithromycin and Hydroxychloroquine in hospitalized patients with confirmed SARS-CoV-2 infection - a randomized placebo-controlled trial (ProPAC-COVID Trial) Source: Virtual Congress 2021 – COVID - 19 treatments Year: 2021 Chinese herbs in treatment of postinfectious cough: A multi-centre, randomized, double-blind, placebo-controlled trial Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Methotrexate in treatment of severe difficult-to-treat asthma: randomized, double-blind, placebo-controlled study Source: Annual Congress 2007 - Towards controlling severe asthma Year: 2007 Randomized double-blind placebo-controlled trial of azithromycin in lung transplantation: first results Source: Annual Congress 2008 - New insights and treatment options for bronchiolitis obliterans syndrome after lung transplantation Year: 2008 Sedation for bronchoscopy in children: a prospective randomized double-blinded trial Source: Virtual Congress 2021 – Posters in paediatric bronchology Year: 2021 Chinese herbs in treatment of influenza: A multi-centre, randomized, double-blind, placebo-controlled trial Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections Year: 2010 Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19 Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19 Year: 2021 A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis Source: Eur Respir J 2014; 43: 1114-1123 Year: 2014 Preventive effect of carbocysteine on exacerbation of asthma, GAIA randomised, placebo-controlled multi-centre study Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Efficacy and costs of telehealth for the management of COPD: PROMETE II, a multicentre, randomized controlled trial Source: International Congress 2017 – New trends in pulmonary rehabilitation and chronic care Year: 2017 PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 A randomized double-blind placebo-controlled trial on the short and long-term effects of electro acupuncture on moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 502s Year: 2006